Jyothy Labs, a mid-tier home and personal care FMCG player with brands such as Ujala, Henko and Exo, has seen its stock correct meaningfully over the past year after an earlier sharp run-up. bl.portfolio had recommended partial profit-booking in July 2024 (₹480 levels) anticipating a moderation in earnings growth after a sharp re-rating. We moved to an accumulate stance in April 2025 (₹360 levels) after the stock corrected.

Jyothy Labs shares have since then corrected further by about 30 per cent over the past year to ₹259.50, underperforming most FMCG peers such as Hindustan Unilever (down 2 per cent), Godrej Consumer (down 7 per cent), Marico (up 10 per cent) and Dabur India (flat), as earnings growth slowed and valuations compressed. Though Colgate-Palmolive, P & G Hygiene and Emami have also corrected 14-24 per cent, Jyothy Labs has been hit the hardest.

While near-term growth remains subdued, early signs of stabilisation in the company are evident. Q3FY26 saw decent volume growth, recovery in personal care and household insecticides, and continued strength in fabric care, alongside improving rural demand and traction in modern trade and e-commerce channels. Other positives include a net-debt free balance sheet, healthy volume growth despite weak pricing, improving mix in liquid detergents and vaporisers, wider direct reach and early repair in loss-making/weak segments.

The stock now trades at about 24 times one-year forward earnings, which is at an attractive 20 per cent discount to its five-year average of about 30 times, and is also cheaper than peers. Thus, the risk-reward has turned more favourable. We, therefore, now recommend long-term investors with a three-five year horizon can buy the stock. We discuss the drivers in detail below.

Business profile

Started in 1983, Jyothy Labs began its journey selling just one brand liquid fabric whitener ‘Ujala Supreme’. Over the years, it has established presence in key categories — fabric care, dish wash, household insecticides and personal care. Its products are available directly in 1.3 million outlets pan-India, boasts of nearly 10,000 channel partners and has nearly two dozen manufacturing plants. In fabric care, it has brands including Ujala, Henko, Mr. White, More Light, Dr.Wool, Super Chek and Speed. In home care, there is Maxo, T-Shine and Maya, while its personal care range spans Margo, Neem Active, FA and Jovia. Dish wash products include Exo and Pril.

Fabric care continues to be the largest (44 per cent of FY25 revenue) segment, followed by dish wash (34 per cent), personal care (11 per cent) and household insecticides (7 per cent).

Volume growth refers to the increase in the number of units sold. Value growth refers to the increase in total revenue from those sales. For 9MFY26, Fabric Care grew 6.2 per cent in value, supported by a robust 7 per cent volume growth and helped by liquid detergents that nearly doubled in both volume and value terms. Personal care segment registered a staid 1.8 per cent value growth, mostly price-led.

However, Dish wash segment experienced a 1.7 per cent decline in value, despite delivering more than 6 per cent volume growth. The management attributed this disconnect to price cuts, extra grammage and promotional offers. Household insecticides revenue was down 3.5 per cent for the nine-month period, still weak but better than the over 7 per cent decline seen in 9MFY25 period.

Financials

For 9MFY26, Jyothy Labs reported an overall revenue growth of 2.2 per cent in value terms and 4.5 per cent in volume growth. Gross margins declined during 9MFY26 to 47.5 per cent from 50.4 per cent, primarily due to MRP cuts and lower sales realisation. This is especially for the dish wash and liquid detergent categories. Advertising and promotion (A&P) spend was about 8 per cent vs. operational revenue in 9MFY26. Sustained brand investments and innovations are key to driving growth.

Elevated input prices of select raw materials, also had an impact, though the management expects gradual stability in raw material prices, going forward. However, geopolitical volatility and forex fluctuations continue to remain watch points. Operating EBITDA margins shrunk by 190 bps to 15.9 per cent, mostly due to gross margin hit. The company is expected to give greater focus on premium product sales and scale-up of new launches, which should ease margin pressures. 9MFY26 PAT stood at ₹266 crore vs. ₹294 crore in the year-ago period. After an estimated 4.1 per cent decline in adjusted EPS for full-year FY26, consensus expects its growth to be over 10 per cent in FY27, per Bloomberg. It has over ₹750 crore of cash.

Catalysts

Growth drivers for Jyothy Labs are more visible now than in the previous few quarters. In Q3FY26, the company reported 7.2 per cent volume growth, with fabric care growing 9.2 per cent in value terms. Within fabric care, the liquid detergent portfolio delivered high double-digit volume growth, while the newly-launched Dr. Wool received a good initial response. Personal care grew 11 per cent in value terms, helped by the Margo franchise returning to profitable growth.

Household insecticides, a weak spot earlier, grew 12.6 per cent in value terms, led by volume growth. The company is reducing focus on coils and shifting towards liquid vaporisers and aerosols, which are better-margin formats. The management expects this category to be completely turned around by the end of FY27. Even dish wash, where value declined due to competitive pricing, saw 7 per cent volume growth.

New products such as Jovia (personal care) and Ujala Instant Dirt Dissolvers in select States have met internal success parameters, as per the management. Jyothy Labs’ laundry business, Fabric Spa (end-to-end garment care, including dry cleaning, wet washing, and doorstep pick-up/delivery), is now a division under the parent company and reported under “others” segment. The company is focused on a retail franchisee model, with over 200 outlets across a few States. The business is growing reasonably, has largely arrested cash losses, and is being gradually moved towards profitability.

Also, growth witnessed in modern trade and quick commerce can support eventual premium product expansion.

Thus, valuations look supportive for Jyothy Labs stock at current levels; as the business steadies, there is scope for a gradual re-rating over the next three-five years.

Published on April 25, 2026